A Fortune 500 company, in conjunction with IBM Watson Health, conducted an economic evaluation to test whether our flagship digital therapeutic for insomnia, Sleepio, would lower health care costs for their employees.
Individuals who used Sleepio had 28% lower annualized total healthcare costs compared to those who did not use Sleepio — demonstrating $1,677 lower health care costs per employee that used Sleepio.
A peek inside:
Read the white paper
Share article
Here’s our latest
Patients initiating pharmacotherapy are generally not receiving guideline-recommended care for insomnia and anxiety
While benzodiazepine and hypnotic medications are generally not indicated as first-line treatments for insomnia and anxiety, an alarming number of…
Report
The impact of good mental health in the retail industry
This report presents all the evidence you’ll need to make the business case for investing in employee mental health.
Report
The impact and value of mental health initiatives by industry sector
Our latest report gives you all the evidence you need to make the case for further investment in employee mental…
Report